Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
80.8M
-
Number of holders
-
115
-
Total 13F shares, excl. options
-
34.6M
-
Shares change
-
+8.09M
-
Total reported value, excl. options
-
$2.04B
-
Value change
-
+$492M
-
Put/Call ratio
-
0.04
-
Number of buys
-
83
-
Number of sells
-
-38
-
Price
-
$58.74
Significant Holders of Kymera Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KYMR) as of Q3 2021
137 filings reported holding KYMR - Kymera Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q3 2021.
Kymera Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KYMR) has 115 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 34.6M shares
of 80.8M outstanding shares and own 42.87% of the company stock.
Largest 10 shareholders include PRICE T ROWE ASSOCIATES INC /MD/ (3.23M shares), BVF INC/IL (3.18M shares), BlackRock Inc. (3.04M shares), VANGUARD GROUP INC (2.9M shares), Redmile Group, LLC (2.79M shares), WELLINGTON MANAGEMENT GROUP LLP (2.47M shares), BAKER BROS. ADVISORS LP (2.38M shares), FMR LLC (2.36M shares), STATE STREET CORP (1.44M shares), and Rock Springs Capital Management LP (733K shares).
This table shows the top 115 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.